Big Pharma doesn’t just “feel” a patent cliff—it reorganizes around it.
When blockbuster revenues start to wobble, the first visible signals often aren’t press releases. They’re quieter: hiring freezes, role reclassifications, vendor swaps, and sudden …

Biosimilar switching isn’t a procurement problem—it’s an IP strategy problem.
If you’re planning a switch from an originator biologic to a biosimilar, the hard part usually isn’t identifying candidates. It’s timing. It’s sequencing. And it’s avoiding t…

Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines
Pharma has a new playbook—and it’s not always about new molecules.
Over the past few years, the industry has increasingly leaned on repurposing: taking an existing dru…

Pharma’s best scientists aren’t always hiding in plain sight—they’re often hiding in the citations.
Recruiters spend months chasing the “perfect” profile: the right therapeutic area, the right publication record, the right company tenure. But in drug d…

Pharma has a familiar playbook: take an old molecule, reframe the evidence, and sell a “new” price.
That’s the core tension behind the industry’s growing use of repurposed medicines—drugs originally approved for one indication, then re-launched for ano…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is a decoy. Patent filings are the real playbook.
If you’ve been watching Russia’s pharmaceutical strategy only through the lens of policy headlines, you’re missing the signal. The most actionable intelligence isn’t in pre…

Europe’s divisional patent game: how “final decisions” get delayed—and why it matters for generics
Big Pharma doesn’t always need to win on the merits. Sometimes it just needs to keep the clock running.
That’s the core story behind Europe’s divisional …

Pharma patent litigation used to be a “cost of doing business.” Now it’s a budget line item that can quietly swallow entire portfolios.
If you’re still planning for $50M+ in legal spend per case, you’re likely building strategy on yesterday’s economics…

PBMs don’t just “manage formularies.” They shape the economics of every branded launch, every contract renegotiation, and—quietly—the fate of pipeline assets that never make it to the pharmacy counter.
If you’re a pharma executive, payer strategy isn’t…